132 related articles for article (PubMed ID: 14534356)
1. Pumping of drugs by P-glycoprotein: a two-step process?
Litman T; Skovsgaard T; Stein WD
J Pharmacol Exp Ther; 2003 Dec; 307(3):846-53. PubMed ID: 14534356
[TBL] [Abstract][Full Text] [Related]
2. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
3. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
4. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells.
Saha P; Yang JJ; Lee VH
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1221-6. PubMed ID: 9620082
[TBL] [Abstract][Full Text] [Related]
5. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia.
Stephens RH; O'Neill CA; Warhurst A; Carlson GL; Rowland M; Warhurst G
J Pharmacol Exp Ther; 2001 Feb; 296(2):584-91. PubMed ID: 11160647
[TBL] [Abstract][Full Text] [Related]
6. Selective modulation of P-glycoprotein-mediated drug resistance.
Bebawy M; Morris MB; Roufogalis BD
Br J Cancer; 2001 Dec; 85(12):1998-2003. PubMed ID: 11747345
[TBL] [Abstract][Full Text] [Related]
7. Cepharanthin, a multidrug resistant modifier, is a substrate for P-glycoprotein.
Hirai M; Tanaka K; Shimizu T; Tanigawara Y; Yasuhara M; Hori R; Kakehi Y; Yoshida O; Ueda K; Komano T
J Pharmacol Exp Ther; 1995 Oct; 275(1):73-8. PubMed ID: 7562598
[TBL] [Abstract][Full Text] [Related]
8. Limited interaction between tacrolimus and P-glycoprotein in the rat small intestine.
Saitoh H; Saikachi Y; Kobayashi M; Yamaguchi M; Oda M; Yuhki Y; Achiwa K; Tadano K; Takahashi Y; Aungst BJ
Eur J Pharm Sci; 2006 May; 28(1-2):34-42. PubMed ID: 16457995
[TBL] [Abstract][Full Text] [Related]
9. Everted rat intestinal sacs: a new model for the quantitation of P-glycoprotein mediated-efflux of anticancer agents.
Carreño-Gómez B; Duncan R
Anticancer Res; 2000; 20(5A):3157-61. PubMed ID: 11062737
[TBL] [Abstract][Full Text] [Related]
10. Modulation of P-glycoprotein-mediated multidrug resistance by acceleration of passive drug permeation across the plasma membrane.
Regev R; Katzir H; Yeheskely-Hayon D; Eytan GD
FEBS J; 2007 Dec; 274(23):6204-14. PubMed ID: 17986257
[TBL] [Abstract][Full Text] [Related]
11. Quinoline derivative KB3-1 potentiates paclitaxel induced cytotoxicity and cycle arrest via multidrug resistance reversal in MES-SA/DX5 cancer cells.
Koo JS; Choi WC; Rhee YH; Lee HJ; Lee EO; Ahn KS; Bae HS; Ahn KS; Kang JM; Choi SU; Kim MO; Lu J; Kim SH
Life Sci; 2008 Nov; 83(21-22):700-8. PubMed ID: 18845169
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
[TBL] [Abstract][Full Text] [Related]
13. Co-treatment with grapefruit juice inhibits while chronic administration activates intestinal P-glycoprotein-mediated drug efflux.
Panchagnula R; Bansal T; Varma MV; Kaul CL
Pharmazie; 2005 Dec; 60(12):922-7. PubMed ID: 16398269
[TBL] [Abstract][Full Text] [Related]
14. The multi-drug resistance reversal agent SR33557 and modulation of vinca alkaloid binding to P-glycoprotein by an allosteric interaction.
Martin C; Berridge G; Higgins CF; Callaghan R
Br J Pharmacol; 1997 Oct; 122(4):765-71. PubMed ID: 9375975
[TBL] [Abstract][Full Text] [Related]
15. A kinetic evaluation of the absorption, efflux, and metabolism of verapamil in the autoperfused rat jejunum.
Johnson BM; Chen W; Borchardt RT; Charman WN; Porter CJ
J Pharmacol Exp Ther; 2003 Apr; 305(1):151-8. PubMed ID: 12649363
[TBL] [Abstract][Full Text] [Related]
16. Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells.
Gayet L; Dayan G; Barakat S; Labialle S; Michaud M; Cogne S; Mazane A; Coleman AW; Rigal D; Baggetto LG
Biochemistry; 2005 Mar; 44(11):4499-509. PubMed ID: 15766280
[TBL] [Abstract][Full Text] [Related]
17. Outward transfer of dopamine precursor L-3,4-dihydroxyphenylalanine (L-dopa) by native and human P-glycoprotein in LLC-PK(1) and LLC-GA5 col300 renal cells.
Soares-Da-Silva P; Serrão MP
J Pharmacol Exp Ther; 2000 May; 293(2):697-704. PubMed ID: 10773046
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy.
Walker J; Martin C; Callaghan R
Eur J Cancer; 2004 Mar; 40(4):594-605. PubMed ID: 14962729
[TBL] [Abstract][Full Text] [Related]
19. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
20. Reversal of P-glycoprotein-mediated multidrug resistance by cholesterol derived from low density lipoprotein in a vinblastine-resistant human lymphoblastic leukemia cell line.
Shu Y; Liu H
Biochem Cell Biol; 2007 Oct; 85(5):638-46. PubMed ID: 17901905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]